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Summary. Background: The K5 polysaccharide obtained
from Escherichia coli strain 010:K5:H4 is a polymer of the
disaccharidic unit formed by D-glucuronic acid and N-
acetylglucosamine. This structure is akin toN-acetylheparosan,
the precursory polymer of heparin and of heparan sulfate. This
structural affinity with N-acetylated heparin and with de-
sulfated heparin makes the K5 polysaccharide extremely useful
for the preparation of sulfated heparin-like semi-synthetic
derivatives. It has been demonstrated that heparins are able to
inhibit tissue factor and cytokine production and expression by
human monocytes. Objective: The aim of this study was to
evaluate the effects of four different heparin-like semi-synthetic
derivatives on inflammatory cytokine production and expres-
sion by human mononuclear cells. Results: The simultaneous
addition of lipopolysaccharide (LPS; 0.2 and 10 lg mL)1) and
the K5 polysaccharide did not inhibit interleukin (IL)-1b, IL-6
or tumor necrosis factor (TNF)-a production by stimulated
mononuclear cells. IL-1b, IL-6 and TNF-a concentrations in
supernatants of LPS-stimulated mononuclear cells were not
influenced by the addition of N,O-sulfated K5 polysaccharide
(K5-N, OS) and epimerized N-sulfated K5 polysaccharide (K5
NS epi) at 5 and 10 lg mL)1, whereas the addition of
epimerized N,O-sulfated K5 polysaccharide (K5-N, OS epi)
(5 and 10 lg mL)1) andO-sulfatedK5polysaccharide (K5-OS)
(5 and 10 lg mL)1) to LPS-stimulated cells caused a significant
dose-dependent inhibition of IL-1b, IL-6 and TNF-a. All
sulfatedheparin-like semi-synthetic derivativesdidnot influence
the IL-10 production by LPS-stimulated mononuclear cells. In
LPS-stimulated cells (0.2 and 10 lg mL)1), K5-OS or K5-N,
OS epi at 5 and 10 lg mL)1 markedly decreased TNF-a
mRNA expression. Conclusions: These results indicate that
the sulfated heparin-like semi-synthetic derivatives K5-OS and
K5-N,OSepi areable to inhibit both expressionandproduction
of inflammatory cytokines, whereas they do not influence the
anti-inflammatory cytokine IL-10, suggesting a potential role
for these products as modulators of inflammatory reactions.
Keywords: heparin derivatives, interleukin 10, proinflamma-
tory cytokines, TNF-alpha mRNA expression.
Introduction
Heparin, a highly sulfated proteoglycan, has several biological
actions independent of its well-known anticoagulant activity,
including the ability to modulate extracellular matrix synthesis,
cellular proliferation, angiogenesis, and particularly inflamma-
tion [1–6]. Mononuclear phagocytes and neutrophils are
actively involved in inflammatory processes and synthesize
and release a number of cytokines such as proinflammatory
interleukins and, therefore, modulate the immune response
through both T and B lymphocytes and the activation of
accessory cells [7]. Lipopolysaccharide (LPS), a major compo-
nent of the outer surface of Gram-negative bacteria, is a potent
modulator of the host immune response and exhibits a variety
of biological effects [8, 9]. A short exposure to LPS is sufficient
to activate monocytes and macrophages to synthesize and
release cytokines such as interleukin (IL)-1b, tumor necrosis
factor (TNF)-a, IL-6, and IL-8, which may induce an
inflammatory state [10]. Interestingly, heparins have been
shown to inhibit proinflammatory cytokine production by
LPS- or interferon-c-stimulated human monocytes even when
heparin is added after stimulation [11] and actively reduce the
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process of leukocyte recruitment into the site of injury [12,13].
In the past years considerable efforts have been made in
developing synthetic oligosaccharides endowed with the anti-
coagulant properties of heparins, but also in identifying the
heparin-like molecule domains associated with anti-inflamma-
tory properties.Wang et al. [13] generated a heparin derivative,
which had a significantly lower anticoagulant activity while
retaining its strong anti-inflammatory activity. In animal
models non-anticoagulant heparinwas able to inhibit leukocyte
adhesion and transmigration in vitro and acute peritonitis and
ischemia and reperfusion injury in vivo by reducing peritoneal
infiltration of neutrophils, tissue edema and leukocyte depos-
ition [13,14]. Furthermore, it has been demonstrated that
heparin oligosaccharides, including non-anticoagulant tetra-
saccharides, are effective L- and P-selectin inhibitors in vitro
and have anti-inflammatory activity in vivo [15]. In addition,
O-desulfated heparin prevented dysfunction of endothelial-
dependent coronary relaxation following ischemic injury and
inhibited translocation of the proinflammatory transcription
nuclear factor-jB (NF-jB) from the cytoplasm to the nucleus
in human endothelial cells and decreasedNF-jBDNAbinding
in human endothelium and ischemic-reperfused rat myocar-
dium [16]. Recently, fucan and dextran derivatives and heparin
were found to modulate, in a dose-dependent manner, the
release of proinflammatory cytokines by resting or LPS-
stimulated human monocytes and to interact with monocyte
surfaces by inhibiting LPS-binding to monocyte membranes
[17].
The aim of this study was to evaluate the effects of four
different heparin-like semi-synthetic derivatives on inflamma-
tory cytokine production and expression by human mononu-
clear cells.
Materials and methods
Cell preparation
Mononuclear cells were obtained from citrated peripheral
blood (1 : 9 v/v). Platelets were removed by centrifugation at
120 · g for 10 min twice; mononuclear cells were separated on
a Ficoll–Hypaque (Nycomed Pharma AS, Oslo, Norway)
gradient [18] andwashed twice with phosphate-buffered saline–
EDTA (NaCl 120 mM, Na2HPO4 10 mM, KH2PO4 3 mM,
EDTA 5 mM) to eliminate further platelet contaminants. They
were then resuspended (1·107 cells mL)1) in RPMI-1640
(GIBCO, Grand Island, NY, USA) containing gentamicin
(100 lg mL)1) (Sigma Chemical Co., St Louis, MO, USA).
Mononuclear cells were>98%viable by trypan blue exclusion
and contained <2% polymorphonuclear leukocytes and
<1% platelets.
Preparation of K5 derivatives
The capsular K5 polysaccharide obtained from Escherichia coli
strain 010:K5:H4 is a polymer with the structure [-4)-GlcA b1-4
GlcNAc-(1-]n in which the disaccharidic units formed by
D-glucuronic acid and N-acetylglucosamine are linked by a
b 1 fi 4 bonds. This structure is similar to N-acetylheparosan,
the precursory polymer of heparin and of heparan sulfate. This
structural affinity with N-acetylated heparin and with desul-
fated heparin makes the K5 polysaccharide extremely useful
for the preparation of sulfated heparin-like semi-synthetic
derivatives. Four classes of sulfated derivatives with different
degrees of N and O sulfation were synthesized: (i) O-sulfated
K5 polysaccharide (K5-OS), obtained by chemical O-sulfa-
tion and N-acetylation of the deacetylated K5 polysaccharide;
(ii) N, O-sulfated K5 polysaccharide (K5-N, OS) obtained by
chemical N and O sulfation after N-deacetylation of K5; (iii)
epimerized N-sulfated K5 polysaccharide (K5-NS epi) ob-
tained by chemical N-sulfation after N-deacetylation of K5
polysaccharide and epimerization with the enzyme glucuronyl
C5 epimerase; (iv) epimerized N and O sulfated K5 polysac-
charide (K5-N, OS epi) obtained by N-desacetylation/
N-sulfation of K5 polysaccharide and epimerization of K5
with the enzyme glucuronyl C5 epimerase and O-sulfation.
The K5 polysaccharide derivatives were obtained from
purified K5 polysaccharide prepared and purified as described
byManzoni et al. [19]. TheK5 derivatives were obtained by the
following procedures.
K5-OS The K5 polysaccharide was treated with 2 M
sodiumhydroxide at 50 C for 18 h and after neutralization the
solution was treated with sodium carbonate and pyridine
sulphur trioxide for 6 h at 55 C. The reaction product was
then passed through a cation-exchange resin (IR-120 H+
BioRad, BioRad Laboratories, Milan, Italy) and treated with
tetrabutylamonium hydroxyde in N,N,DMF. O-sulfation was
carried out at 50 C for 24 h with pyridine sulphur trioxide.
The O-sulfated product was finally solubilized in deionized
water at room temperature and added to sodium hydroxide
and acetic anhydride.
K5-N, OS O-sulfated derivatives obtained with the
above procedure were treated with sodium carbonate and
pyridine sulphur trioxide up to 6 h at 55 C and samples were
purified from salts by ultrafiltration to obtain N, O-sulfted K5
polysaccharides.
K5-NS epi N-deacetylated/N-sulfated K5 polysaccha-
ride obtained as above was treated with recombinant glucuro-
nyl C5 epimerase immobilized on a CNBr Sepharose 4B resin
(Pharmacia, Uppsala, Sweden). The reaction was carried out at
37 C for 24 h by passing the substrate dissolved in 25 mM
HEPES buffer, pH 6.5 50 mM CaCl2, through the column.
The epimerized product was then purified by ultrafiltration and
precipitation.
K5-N, OS epi The epimerized N-sulfated K5 derivative
obtained as above was dissolved in water, passed through a
cation-exchange resin, reacted with an organic base, dissolved
in N,N,DMF and O-sulfated at 50 C for 24 h with pyridine
sulphur trioxide.
All the samples were characterized by nuclear magnetic
resonance analysis, sulphate/carboxyl ratio analysis, molecu-
lar weight determination, according to described methods
[20].
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All heparin-like derivative molecules were also tested for
their antithrombotic/anticoagulant activity, showing no or very
little (< 10 IU mg)1) anti-factor Xa activity.
Cell stimulation
Human mononuclear cells isolated from 10 healthy male
subjects were stimulated with LPS (0.2 and 10 lg mL)1) and
incubated (107 cells mL)1) with four sulfated derivatives (5 or
10 lg mL)1) with different degrees of N and O sulfation at
37 C at 0 (PBS buffer), 5 and 10 lg mL)1 for 4 h: (i)
O-sulfated K5 polysaccharide (K5-OS), (ii) N,O-sulfated K5
polysaccharide (K5-N, OS), (3) epimerized N sulfated K5
polysaccharides (K5-NS epi), and (iv) epimerized N and
O sulfated K5 polysaccharides (K5-N, OS epi).
Cytokine determination
After incubation, mononuclear cells were centrifuged and in
the supernatants IL1-b, IL-6, IL-10 and TNF-a concentra-
tions were determined using ELISA methods (Amersham
Pharmacia Biotech). The minimum detectable concentrations
were 0.10 pg mL)1 for IL1-b, IL-6, TNF-a and 3 pg mL)1
for IL-10. The interassay coefficient of variation was 7.0%
for all assays.
RNA preparation
Total RNA was extracted from mononuclear cells using a
guanidium thiocyanate single-step isolation method [21]. Total
RNA concentrations were determined by spectrophotometry.
Reverse transcription
Total RNA was first heated at 65C for 5 min. First-strand
cDNA was synthesized using 1mg total RNA 10ml)1 of final
reaction volume containing 50 mM Tris–HCL pH 8.3, 3 mM
MgCl2, 10 mM DTT (GIBCO), 75 mM KCL, 0.125 mM each
dGTP, dATP, dTTP, dCTP (Pharmacia Biotech), 1.5 ng mg)1
random esanucleotide primer (Pharmacia Biotech), 100 U of
reverse transcriptase (GIBCO) and incubated at 37 C for 90min.
TaqMan polymerase chain reaction
TNF-a primers and probes were purchased fromABI (Applied
Biosystem ABI, Foster City, CA, USA). TaqMan polymerase
chain reaction (PCR) was performed with 5 lL of Reverse
Transcriptase (RT) diluted products (50 ng of total RNA) in a
total volume of 25 lL of 1 · TaqMan Mastermix (ABI)
containing 100 nM forward and reverse primers and 100 nM
probe. Thermocycling conditions were: 50 C for 2 min, 95 C
for 10 min and run 40 cycles at 95 C for 15 s, 60 C for 1 min
on theABI Prism 7700Detection System (ABI). The reaction is
based on the use of fluorogenic probes designed to hybridize to
the gene target sequence of the two PCR primers. Each probe
contains a fluorescent reporter dye and a quencher dye at the
5¢ and 3¢ ends, respectively. In the intact probe the presence of
the quencher inhibits reporter emission by quenching energy
emission. During the extension phase of PCR cycling, the
annealed probe is cleaved by the exonuclease activity of Taq
polymerase. The cleavage produces an increase of fluorescence
emission of reporter dye. This event occurs in each PCR cycle
only if probe is annealed to the target sequence, which leads to
an increase of fluorescence proportional to the concentration of
target sequences in the initial sample.
The threshold cycle (CT) represents the PCR cycle at which
an increase in reporter fluorescence above a baseline signal can
first be detected.
The percentage of TNF-a mRNA inhibition by semi-
synthetic derivatives after LPS stimulus was calculated in each
experiment referring the sample CT (threshold cycle) value to
the LPS-stimulated cell CT value of the same experiment. The
LPS-stimulated cell CT value was considered 100% of mRNA
expression in each experiment.
Statistical analysis
The tests were performed by SPSS (Chicago, IL, USA) 11.5
software forWindows. The results presented are themean of 10
independent experiments with 10 different donors. The
percentage inhibition of cytokine production was relative to
the amounts of cytokines produced in the LPS-stimulated
samples in the absence of heparin derivatives, which was taken
as 100%. Results given as mean ± standard deviation. The
statistical analysis were performed using analysis of variance
(ANOVA) followed by the Dunnet’s test for multiple compar-
ison. AllP-values reported are two-tailed with values of<0.05
considered statistically significant.
Results
The incubation of mononuclear cells with the heparin deriv-
atives (5 or 10 lg mL)1) did not cause any significant decrease
in cell viability (data not shown).
LPS at 0.2 and 10 lg mL)1 markedly stimulated mononu-
clear cell IL-1b, IL-6, IL-10 and TNF-a production (data not
shown).
As shown in Table 1, the simultaneous addition of LPS
(0.2 lg mL)1) and the K5 polysaccharide (starting material)
(10 lg mL)1), K5-N, OS and K5-NS epi at 5 and 10 lg mL)1
to cellular suspensions did not inhibit IL-1b, IL-6 or TNF-a
production by stimulated mononuclear cells, whereas the
addition of K5-OS (5 and 10 lg mL)1) and K5-N, OS epi
(5 and 10 lg mL)1) to LPS-stimulated cells (0.2 lg mL)1)
caused a significant (P < 0.05) decrease of IL-1b, IL-6 and
TNF-a production (Table 1). The inhibitory effect of heparin
derivative K5-OS seemed to be dose dependent: K5-OS
(5 lg mL)1) decreased 25.4 ± 14.03% of IL-1b,
10.63 ± 7.18% of IL-6 and 22.15 ± 17.61% of TNF-a
production by LPS-stimulated mononuclear cells
(0.2 lg mL)1). We also observed a greater inhibitory effect on
cytokine productionwhenK5-OSwas added at a concentration
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of10 lg mL)1: 36.92 ± 11.9%for IL-1b, 38.75 ± 14.61%for
IL-6, and 36.30 ± 17.1% for TNF-a. The inhibitory effect on
IL-1b, IL-6 and TNF-a of K5-N, OS epi at 5 lg mL)1 was
23.5 ± 14.7% for IL-1b, 22.61 ± 9.7% for IL-6 and
23.75 ± 13.23% for TNF-a. K5-N, OS epi at 10 lg mL)1
inhibited 41.3 ± 16.80% of IL-1b, 43.36 ± 12.37 % of IL-6
and 42.50 ± 18.50 % of TNF-a production.
The simultaneous addition of LPS 10 lg mL)1 and the K5
polysaccharide (starting material) (10 lg mL)1), K5-N, OS
andK5-NS epi at 5 and 10 lg mL)1 to cellular suspensions did
not cause any significant inhibition of IL-1b, IL-6 or TNF-a
production (Table 2), whereas the addition of K5-OS (5 and
10 lg mL)1) and K5-N, OS epi (5 and 10 lg mL)1) to LPS-
stimulated cells (10 lg mL)1) caused a significant (P < 0.05)
decrease of IL-1b, IL-6 and TNF-a production (Table 2).
The addition to cellular suspensions of all sulfated heparin-
like semi-synthetic derivatives did not cause a significant
inhibition of the production of the anti-inflammatory cytokine
IL-10 by LPS-stimulated mononuclear cells (0.2 lg mL)1).
Mononuclear cells stimulated by 0.2 lg mL)1 of LPS
produced 16.1 ± 8.1 pg mL)1 of IL-10. LPS (0.2 lg mL)1)-
stimulated cells, treated with K5-N,OS, or K5-N OS epi, or
K5-OS or K5-NS epi, at 10 lg mL)1 produced 16.5 ± 8.3,
16.3 ± 8.3, 16.7 ± 9.5, 16.8 ± 8.9 pg mL)1 of IL-10 respect-
ively. Mononuclear cells stimulated with 10 lg mL)1 of LPS
produced 96.2 ± 63.0 pg mL)1 of IL-10. The simultaneous
addition of the heparin derivatives at 10 lg mL)1 to LPS
(10 lg mL)1)-stimulated mononuclear cells did not signifi-
cantly influence IL-10 production (K5-N,OS 99.1 ± 64.9;
K5-N OS epi 98.7 ± 63.8; K5-OS 97.9 ± 66.2; or K5-NS epi
98.7 ± 63.8 pg mL)1).
The addition of either K5-OS or K5-N, OS epi at 5 and
10 lg mL)1 in LPS (0.2 lg mL)1)-stimulated mononuclear
cells resulted in a dose-dependent inhibition of TNF-amRNA
expression: K5-OS at 5 and 10 lg mL)1 inhibited 40.9% (from
10.0% to 74.0% ) and 58.8 % (from 12.0% to 86.0%) of
TNF-a mRNA expression, respectively. K5-N, OS epi at
5 and 10 lg mL)1 inhibited 68.0% (from 10.0% to 100.0%),
and 94.3 % (from 46.0% to 100.0%) of TNF-a mRNA
expression. Similar results were obtained when mononuclear
cells were stimulated with 10 lg mL)1 of LPS: 5 lg mL)1 K5-
OS inhibited 38.1% (from 10.0% to 68.0% ), 10 lg mL)1
K5-OS 64.2% (from 12.0% to 88.0%), 5 lg mL)1 K5-N, OS
epi 63.0% (from 9.0% to 100.0%), and 10 lg mL)1 K5-N, OS
epi 92.3 % (from 46.0% to 100.0%) of TNF-a mRNA
expression by LPS (10 lg m:)1)-stimulated cells.
No inhibition of TNF-a mRNA expression was observed
when the other sulfated polysaccharide derivatives K5-N,OS
and K5-NS epi at 5 and 10 lg mL)1 were added after 3 h
stimulation (data not shown).
Table 2 Effects of different heparin-like semi-synthetic derivatives on cytokine production (ng per 107 cells) by lipopolysaccharide (LPS) (10 lg mL)1)-
stimulated mononuclear cells
IL-1b production IL-6 production TNF-a production
LPS (10 lg mL)1) + RPMI medium 5.61 ± 1.77 9.61 ± 4.35 7.88 ± 4.69
LPS (10 lg mL)1) + K5 10 lg mL)1 5.59 ± 1.57 9.51 ± 4.34 8.10 ± 4.84
LPS (10 lg mL)1) + K5-OS (5 lg mL)1) 4.37 ± 1.39* 8.82 ± 4.01* 6.12 ± 3.68*
LPS (10 lg mL)1) + K5-OS (10 lg mL)1) 3.61 ± 1.29** 6.41 ± 3.46** 4.96 ± 2.90**
LPS (10 lg mL)1) + K5-N, OS (5 lg mL)1) 5.68 ± 1.74 9.62 ± 4.46 8.07 ± 4.64
LPS (10 lg mL)1) + K5-N, OS (10 lg mL)1) 5.69 ± 1.62 9.17 ± 3.97 7.78 ± 4.74
LPS (10 lg mL)1) + K5-NS Epi (5 lg mL)1) 5.63 ± 1.77 9.68 ± 4.21 7.79 ± 4.61
LPS (10 lg mL)1) + K5-NS Epi (10 lg mL)1) 5.71 ± 2.15 9.42 ± 4.19 7.85 ± 4.57
LPS (10 lg mL)1) + K5-N, OS Epi (5 lg mL)1) 4.24 ± 1.39* 7.60 ± 3.52§ 6.10 ± 3.13*
LPS (10 lg mL)1) + K5-N, OS Epi (10 lg mL)1) 3.41 ± 1.51** 5.62 ± 2.59** 4.91 ± 3.35**
*P < 0.05 vs. LPS; §P < 0.01 vs. LPS; **P < 0.001 vs. LPS.
Table 1 Effects of different heparin-like semi-synthetic derivatives on cytokine production (ng per 107 cells) by lipopolysaccharide (LPS) (0.2 lg mL)1)-
stimulated mononuclear cells
IL-1b production IL-6 production TNF-a production
LPS (0.2 lg mL)1) + RPMI medium 0.93 ± 0.35 1.09 ± 0.53 0.99 ± 0.98
LPS (0.2 lg/ml) + K5 10 lg mL)1 0.92 ± 0.35 1.08 ± 0.54 0.97 ± 0.96
LPS (10 lg mL)1) + K5-OS (5 lg mL)1) 0.69 ± 0.29* 0.98 ± 0.50* 0.81 ± 0.89*
LPS (0.2 lg mL)1) + K5-OS (10 lg mL)1) 0.60 ± 0.29** 0.69 ± 0.44** 0.61 ± 0.38**
LPS (0.2 lg mL)1) + K5-N, OS (5 lg mL)1) 0.92 ± 0.36 1.07 ± 0.53 0.98 ± 0.97
LPS (0.2 lg mL)1) + K5-N, OS (10 lg mL)1) 0.91 ± 0.34 1.06 ± 0.18 0.98 ± 0.98
LPS (0.2 lg mL)1) + K5-NS Epi (5 lg mL)1) 0.92 ± 0.36 1.08 ± 0.53 0.98 ± 0.95
LPS (0.2 lg mL)1) + K5-NS Epi (10 lg mL)1) 0.90 ± 0.33 1.07 ± 0.53 0.99 ± 0.98
LPS (0.2 lg mL)1) + K5-N, OS Epi (5 lg mL)1) 0.71 ± 0.28* 0.85 ± 0.42§ 0.72 ± 0.65*
LPS (0.2 lg mL)1) + K5-N, OS Epi (10 lg mL)1) 0.56 ± 0.29** 0.61 ± 0.29** 0.53 ± 0.66**
*P < 0.05 vs. LPS; §P < 0.01 vs. LPS; **P < 0.001 vs. LPS.
1660 A. M. Gori et al
 2004 International Society on Thrombosis and Haemostasis
Discussion
Our results demonstrate that sulfated heparin-like semi-
synthetic derivatives and in particular the K5-OS and K5-N,
OS epi are able to inhibit in a dose-dependent manner both
expression and production of inflammatory cytokines, whereas
they do not influence anti-inflammatory IL-10 production by
LPS-stimulated human mononuclear cells, suggesting a poten-
tial role for these compounds as anti-inflammatory agents.
During immune and inflammatory processes the proinflam-
matory cytokines IL-1b, IL-6 and TNF-a increase many times
their levels in the circulation or locally. The synthesis of several
proinflammatory cytokines is inhibited by the anti-inflamma-
tory cytokine IL-10, which is an important immunoregulatory
cytokine produced by B and T lymphocytes and monocytes
and macrophages [22].
Heparin is a glycosaminoglycan composed of alterning
D-glucosamine and uronic acid (L-iduronic or D-glucuronid
acid) residues that are heterogeneous in size and degree of
sulfation. It is well known that the anticoagulant properties of
heparin depend on the presence of a specific pentasaccharide
sequence with high affinity to antithrombin, which enhances its
inhibitory action against serine protease. Heparin, in addition
to its well-known anticoagulant properties, is endowed with
inhibitory activities on proinflammatory cytokines, as demon-
strated in in-vitro studies, in which cytokine production and
expression by stimulated monocytes [11, 12] decreased in the
presence of unfractionated heparin. After the development of
synthetic oligosaccharides, in-vitro and in-vivo studies have
documented that heparan sulphate and heparin derivatives are
able to bind to and regulate the metabolism of several growth
factors, as well as to L-, and P-selectin [4, 6, 15, 23, 24].
In our study, the inhibitory effect of two semi-synthetic
O-sulfated heparin derivatives (K5-OS and K5-N, OS epi) on
cytokine production and expression is likely to be specific, as
this effect is associated with a particular chemical and
enzymaticmodification of thesemolecules. In fact, the chemical
modifications of the starting material (K5 polysaccharide) in
terms of N-acetylation and O-sulfation enable this molecule to
inhibit cytokine production and expression differently from
that observed with K5-N, OS and K5-NS epi molecules, which
do not contain N-acetyl groups, suggesting that N-acetylation
is required for anti-inflammatory activity of the O-sulfated
molecules. These data are in accordance with different studies,
in which N-acetyl heparin was found to specifically bind and
inhibit growth factors as well as complement components
[5,25,26].
Other structural modifications, regarding the degree of
sulfation and the localization of the sulphate groups,
ameliorate the capability of heparin derivatives to interact
with cells involved in the inflammatory processes [26–29]. In a
recent report, it was also demonstrated that the interaction of
heparin with P- and L-selectins is critically related to the
presence of the 6-O-sulphate group and in addition the
2-O,3-O desulfation of heparin generated a potent, non-
anticoagulant, anti-inflammatory activity, suggesting that
appropriate sulfation of heparins plays a critical role in
selectin recognition and binding [23].
In our study, the N and O-sulfation of the starting material
(K5), which determines the formation of K5-N, OS polysac-
charide, seems not to influence its anti-inflammatory activities
(K5-N, OS does not decrease cytokine production and
expression). On the other hand, the enzymatic modification
of K5-N, OS by C5-epimerase produces a conformational
change in the molecule and enables its anti-inflammatory
activity, suggesting that, in addition to N-acetylation, epime-
rization is also necessary for cytokine inhibition. The possible
role of the heparin derivatives rich in sulfated and epimerized
regions is underlined by a recent study in which it was found
that the L- and P-binding fragments include a more heavily
sulfated and epimerized region [30].
A direct effect on TNF-amRNA and cytokine proteins and
an interference of the heparin-like molecules with the experi-
mental procedures used for cytokine determination and
mRNA quantification can be ruled out, as the addition of
these molecules at the end of incubation did not modify
cytokine production and TNF-a mRNA expression.
As the mechanisms possibly responsible for cytokine inhi-
bition are concerned, different aspects have to be considered.
First, the ability of heparin molecules to bind electrostatically
to cell membranes of different cells and to internalize into the
cytosolic compartment causes the inhibition of proinflamma-
tory nuclear transcription factor activation by preventing the
translocation of NF-jB from the cytoplasm to the the nucleus.
Second, inhibition at a transductional level should be consid-
ered. However, our experiments cannot rule out that heparin-
like molecules affect the stability of mRNA.
In conclusion, we have demonstrated that specific struc-
tural modifications [chemical (N-acetylation) and enzymatic
modification (C5 epimerization)] of O-sulfated heparin-like
molecules enable the inhibition of proinflammatory cytokines,
without affecting the anti-inflammatory cytokine IL-10,
suggesting a potential role for these molecules as anti-
inflammatory agents. Heparin is known to have inhibitory
effects on multiple components of the inflammation cascade,
including integrins, cytokines, neutrophil-derived elastases
and complement activation, but its use in clinical practice as
an anti-inflammatory drug is restricted by the potential for
bleeding.
The heparin-like molecules developed for this study show
anti-inflammatory activities and low anticoagulant activities, so
encouraging continuation of the development of specific
structuralmodification ofK5 selectively sulfatedK5 derivatives
in order to obtain inhibitors that might interfere with
inflammatory processes.
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